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PTEN is a lipid phosphatase responsible for down-
regulating the phosphoinositide 3-kinase product phos-
phatidylinositol 3,4,5-triphosphate. Phosphatidylinosi-
tol 3,4,5-triphosphate is involved in the activation of the
anti-apoptotic effector target, Akt. Although the Akt
pathway has been implicated in regulating NF-B activ-
ity, it is controversial as to whether Akt activates NF-B
predominantly through mechanisms that regulate nu-
clear translocation or transactivation potential. In this
report, we utilized PTEN as a natural biological inhibi-
tor of Akt activity to study the effects on tumor necrosis
factor (TNF)-induced activation of NF-B. We found that
the reintroduction of PTEN into prostate cells inhibited
TNF-stimulated NF-B transcriptional activity. PTEN
failed to block TNF-induced IKK activation, IB degra-
dation, p105 processing, p65 (RelA) nuclear transloca-
tion, and DNA binding of NF-B. However, PTEN inhib-
ited NF-B-dependent transcription by blocking the
ability of TNF to stimulate the transactivation domain
of the p65 subunit. PTEN also inhibited the transactiva-
tion potential of the cyclic AMP-response element-bind-
ing protein, but this was not observed for c-Jun. The
transactivation potential of p65 following TNF stimula-
tion could be rescued from PTEN-dependent repression
by re-introducing expression constructs encoding acti-
vated forms of phosphoinositide 3-kinase, Akt, or Akt
and IKK. The ability of PTEN to inhibit the TNF-induced
transactivation function of p65 is important, because
expression of PTEN blocked TNF-stimulated NF-B-de-
pendent gene expression, thus sensitizing cells to TNF-
induced apoptosis. Maintenance of the PTEN tumor sup-
pressor protein is therefore required to modulate Akt
activity and to concomitantly control the transcrip-
tional activity of the anti-apoptotic transcription factor
NF-B.
PTEN, also known as MMAC1 or TEP1, is a tumor suppres-
sor gene inactivated in many common malignancies, including
glioblastoma, melanoma, endometrial, lung, and prostate can-
cer (1–5). The genetic evidence that PTEN is an important
tumor suppressor protein is supported by the fact that het-
erozygous disruption of the PTEN gene in knockout mice re-
sults in the spontaneous development of tumors late in life (6).
PTEN has been implicated in regulating cell survival signaling
through the phosphatidylinositol 3-kinase (PI3K)1/Akt path-
way. PTEN dephosphorylates the D3 position of the key lipid
second messenger phosphatidylinositol 3,4,5-triphosphate
(PIP3) (6–8). PIP3, produced by PI3K following activation by
receptor tyrosine kinases, activated Ras, or G proteins, leads to
the stimulation of several downstream targets, including the
serine/threonine protein kinase Akt (also known as protein
kinase B) (1–5). Activated Akt protects cells from apoptotic
death by phosphorylating substrates such as BAD, pro-
caspase-9, and forkhead transcription family members (9–11).
Akt has also been shown to prolong cell survival by delaying
p53-dependent apoptosis (12). Recently, Akt has been proposed
to regulate permeability transition pore opening within the
mitochondrial membrane by increasing the coupling of glucose
metabolism to oxidative phosphorylation (13). Finally, multiple
laboratories have demonstrated that the PI3K/Akt pathway
provides cell survival signals, in part, through the activation of
the NF-B transcription factor (14–17).
NF-B, classically a heterodimer composed of the p50 and
p65 subunits, is a transcription factor whose activity is tightly
regulated at multiple levels (18–21). NF-B is normally se-
questered in the cytoplasm as an inactive complex bound by an
inhibitor known as IB (18). Following cellular stimulation,
IB proteins become phosphorylated by the IB kinase (IKK),
which subsequently targets IB for ubiquitination and degra-
dation through the 26 S proteasome (20). The degradation of
IB proteins liberates NF-B, allowing this transcription factor
to translocate to the nucleus. In addition to regulation by IB,
NF-B is also regulated by phosphorylation events that posi-
tively up-regulate the transactivation potential of NF-B sub-
units (22). The transactivation domains of NF-B have been
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shown to be regulated by the catalytic domain of protein kinase
A, casein kinase II, and by IKK itself (23–27). Although signals
that regulate nuclear translocation of NF-B have been re-
garded as the primary mechanism of NF-B activation, alter-
native mechanisms involving the transactivation potential of
p65 have been shown to be critical for NF-B activation in vitro
and in vivo (22, 28, 29).
Several different laboratories, including our own, have
shown that various growth factors, cytokines, and oncogenes
require PI3K- and Akt-dependent pathways for full NF-B
activation (30–36). Despite this consensus, the exact mecha-
nism by which Akt pathways activate NF-B remains contro-
versial (37). Activation of the Akt pathway has been reported to
stimulate IKK-dependent IB degradation and nuclear trans-
location of NF-B (14, 31). Other reports including our own (15,
30, 36) have shown that Akt-dependent activation of NF-B
occurs predominantly by stimulating the transactivation po-
tential of the p65 subunit, rather than inducing signals that
result in NF-B nuclear translocation via IB degradation.
Recently, two reports (38, 39) from independent laboratories
analyzed the effects of PTEN-dependent inhibition of the PI3K
and Akt pathway on cytokine-induced activation of NF-B.
Both reports concluded that PTEN expression blocked IL-1 or
TNF-induced NF-B activation; however, major discrepancies
exist between these two studies. Koul et al. (38) showed that
PTEN-dependent inhibition of Akt failed to block IL-1-in-
duced IB degradation and nuclear translocation of p65 but
rather inhibited NF-B-DNA binding. In this study, it was
proposed that PTEN functioned to inhibit phosphorylation of
the p50 subunit of NF-B, thus inhibiting the DNA binding
potential of NF-B (38). In contrast, Gustin et al. (39) reported
that PTEN inhibited NF-B transcriptional activity by impair-
ing TNF-induced activation of Akt and the IKK complex, sug-
gesting that the PTEN-mediated inhibition of IKK activity
blocked the TNF-induced nuclear translocation and DNA bind-
ing potential of NF-B. Although both of these studies (38, 39)
demonstrate that PTEN is capable of inhibiting cytokine-in-
duced activation of NF-B, it remains ambiguous as to whether
PTEN-dependent inhibition of Akt inhibits NF-B by down-
regulating signals that control nuclear translocation, DNA
binding, and/or transactivation potential of NF-B.
To address the involvement of PI3K and Akt in TNF-induced
activation of NF-B, we utilized PTEN-deficient prostate cell
lines that constitutively express activated Akt because of a loss
of PTEN lipid phosphatase activity (40, 41). In this study, we
demonstrate that re-introduction of PTEN into prostate cells
results in a down-regulation of Akt activity and a loss of TNF-
induced NF-B-dependent transcription without blocking IKK-
induced IB degradation, p105 processing, p65 nuclear trans-
location, or NF-B DNA binding activity. However, we find that
neither Akt nor IKK is dispensable for TNF to stimulate the
transactivation potential of the p65 subunit of NF-B in pros-
tate epithelial cells. We demonstrate that PTEN elicits selec-
tive inhibition by blocking signal transduction pathways that
are responsible for targeting the transactivation potential of
NF-B and CREB but not for c-Jun. The ability of PTEN to
inhibit Akt activity and subsequently block TNF-induced tran-
scriptional activity of NF-B led to abrogation of the anti-
apoptotic function of NF-B. This work demonstrates that re-
introduction of PTEN sensitizes prostate epithelial cells to
TNF-induced apoptosis, in part by down-regulating the trans-
activation potential of NF-B. Thus, NF-B is a relevant target
of the tumor suppressor function of PTEN.
MATERIALS AND METHODS
Cell Culture, Reagents, and Plasmid Constructs—Human prostate
cancer cells, LNCaP, were grown in T-media (Invitrogen) supplemented
with 10% fetal calf serum (HyClone Laboratories, Logan, UT) and
penicillin/streptomycin. PC-3 and DU-145 cells were cultured in Dul-
becco’s modified Eagle’s medium-H (Invitrogen) supplemented with
10% fetal bovine serum and penicillin/streptomycin. The 3-B lucif-
erase (3-B-Luc) reporter construct contains four NF-B DNA-bind-
ing consensus sites originally identified in the MHC class I promoter,
fused upstream to firefly luciferase (42). The Gal-4 luciferase construct
(Gal4-Luc) contains four Gal-4 DNA-binding consensus sites, derived
from the yeast GAL-4 gene promoter, cloned upstream of luciferase
cDNA (42). Plasmids encoding the Gal4-p65 fusion protein have the
yeast Gal-4 DNA binding domain fused to the transactivation domain 1
(TA1) of NF-B (43). Gal4-cJun-(1–223) and Gal4-CREB-(1–283) were
commercially purchased (Stratagene, La Jolla, CA). His-tagged -ga-
lactosidase encoding plasmid pCMV-LacZ was obtained from Invitro-
gen. Expression plasmids encoding constitutively activated Ha-
Ras(V12), PI3K*, myristoylated Akt (M-Akt), and wild-type IKK
(wtIKK) and plasmids encoding dominant negative PI3K (p85), Akt(K-
M), and IKK(SS  AA) proteins have been described previously (15).
Plasmids encoding constitutively active FLAG-tagged CaMKKc were
described previously (44). The expression vectors pcDNA3-PTENwt and
pcDNA3-PTEN C124S have been described previously (41). The PTEN
G129E mutant was constructed using the Quikchange site-directed
mutagenesis kit (Stratagene) and verified by DNA sequence analysis.
Recombinant human TNF was obtained from Promega (Madison, WI).
PTEN (N19), His epitope tag (G-18), IB (C-21), p50 (N19), and Gal-4
(N19) antibodies were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Pan-Ras antibody (Ab-4) was purchased from Calbiochem.
Phospho-Akt-specific (Ser-473), pan-Akt, and IKK antibodies were
obtained from New England Biolabs (Beverly, MA). p65-specific anti-
body was obtained through Rockland (Gilbertsville, PA), and M2 FLAG
epitope tag and -tubulin (T9026) were obtained from Sigma. The
proteasome inhibitor MG132 (C2211) was obtained from Sigma.
Transfection and Luciferase Reporter Assays—LNCaP cells at 60–
80% confluency were transiently transfected using Superfect reagent
(Qiagen, Valencia, CA) according to the manufacturer’s instructions.
Briefly, plasmid constructs (1 g of DNA total) were diluted in serum-
free media and mixed with the Superfect reagent. Complexes were
allowed to form for 10 min before serum-containing media were added
to the mixture. The cells were washed once with 1 phosphate-buffered
saline, and Superfect-DNA complexes were added to the cells and
placed in a humidified incubator at 37 °C with 5% CO2. Three hours
following the start of transfection, cells were washed with 1 phos-
phate-buffered saline and replenished with fresh serum-containing me-
dia. Twenty four hours post-transfection, cells were washed once with
1 phosphate-buffered saline and lysed in 0.25 M Tris-HCl (pH 7.4)
following three freeze-thaws in a dry-ice/ETOH bath. Extracts were
collected and cleared by centrifugation at 14,000 rpm. Protein concen-
trations were determined with the Bio-Rad protein assay dye reagent.
Luciferase assays were performed on equal amounts of protein (100
g/sample). D-Luciferin was used as a substrate, and relative light units
were measured using an AutoLumat LB953 luminometer (Berthold
Analytical Instruments). For control purposes, all cell groups that re-
ceived PTEN were also co-transfected with pCMV-LacZ and assayed for
transfection efficiency by counting -galactosidase-positive cells as de-
scribed previously (45).
Adenovirus Construction and Infection—Ad-PTEN is a replication-
defective E1-deleted adenovirus expressing PTEN under the control of
the cytomegalovirus promoter. Recombinant PTEN adenovirus was
constructed as described previously (46). Recombinant virus was
plaque-purified three times, and the structure was verified by restric-
tion mapping of Hirt supernatant DNA. Ad-GFP, similarly constructed,
expresses enhanced green fluorescent protein and was provided by Dr.
Lily Wu (UCLA). Adenovirus was amplified in 293 cells and purified by
banding in a cesium chloride density gradient.
Electrophoretic Mobility Shift Assays and Western Blot Analysis—
Preparation of nuclear and cytoplasmic extracts and electrophoretic
mobility shift assays (EMSAs) were performed as described previously
(42). Briefly, nuclear extracts were prepared at the indicated times and
incubated with [32P]dCTP-labeled, double-stranded probe containing an
NF-B consensus site from the class I major histocompatibility complex
(MHC) promoter. Labeled probe-nuclear complexes were incubated for
10 min at room temperature and separated on a 5% polyacrylamide gel.
Subsequently, the gel was dried and exposed to x-ray film. Western blot
analysis was performed by either analyzing 0.25 M Tris-HCl-lysed cell
extracts or cytoplasmic and nuclear proteins on a 10% SDS-polyacryl-
amide gel. Total protein (50 g) was separated by SDS-PAGE and
transferred to nitrocellulose membranes. The indicated primary anti-
bodies were incubated for 30 min, washed, and visualized by incubation
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FIG. 1. PTEN inhibits NF-B-dependent transcription in response to TNF. A, the lipid phosphatase activity of PTEN is required to
suppress TNF-induced activation of NF-B. LNCaP cells were transiently co-transfected with an NF-B-responsive reporter (3-B-Luc, 0.5 g)
and the control plasmid (pCMV-LacZ) encoding the -galactosidase enzyme. In addition, cells were also co-transfected with expression plasmids
encoding wild-type PTEN, mutant PTEN(C124S), PTEN(G129E), or empty vector control (1 g each). Eighteen hours following transfection,
LNCaP cells were stimulated with TNF (10 ng/ml). Cell lysates were harvested 12 h post-TNF stimulation, and luciferase activity was assayed.
Data are presented as fold activation, where the values obtained for the vector control group were normalized to 1. Results represent the mean 
S.D. of three independent experiments performed in triplicate. Bottom panel, total protein was isolated from a representative transfection
experiment, and immunoblot analysis was performed for PTEN and His-tagged -galactosidase (-Gal) as described under “Materials and
Methods.” B, PTEN inhibits Ha-Ras(V12)-induced activation of NF-B. LNCaP cells were co-transfected with 3-B-Luc (0.5 g) and with empty
vector control plasmid or expression constructs encoding constitutively active Ha-Ras(V12) or CaMKK (1 g each). In addition, cells were also
co-transfected with either empty vector control or with wild-type PTEN (1 g each). Luciferase activities were determined 24 h following
transfection. Data represent three individual experiments performed in triplicate. Western blot analysis confirmed the expression of PTEN,
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with horseradish peroxidase-conjugated secondary antibodies and ECL
chemiluminescent reagents (Amersham Biosciences).
IKK Immunokinase Assay—Subconfluent LNCaP cells infected with
either Ad-GFP or Ad-PTEN for 48 h were either left untreated or were
stimulated with 10 ng/ml TNF for 15 min. Whole cells extracts were
immunoprecipitated with an antibody against IKK (New England
Biolabs), and the immunoprecipitates were subject to an IKK assay (26)
using GST-IB-(1–54) (4 g) as a substrate. Samples were resolved on
SDS-PAGE gels, dried, and subjected to autoradiography. Immunopre-
cipitated protein complexes were also analyzed by Western blot analy-
sis to confirm that equal amounts of IKK had been analyzed during the
IKK assay. Whole cell lysates were analyzed by Western blot analysis
for PTEN expression.
Northern Blot Analysis—Logarithmically growing LNCaP cells were
infected with either Ad-GFP or Ad-PTEN virus. Twenty four hours
later, cells were either left untreated (t0) or stimulated with TNF (10
ng/ml). Total RNAs were isolated using Trizol reagent (Invitrogen).
RNAs (15 g/lane) were resolved on a denaturing 1.8% agarose-for-
maldehyde gel, transferred to Hybond membrane (PerkinElmer Life
Sciences), and crossed-linked. Gene expressions were determined by
analyzing Northern blots with 32P-labeled random probes generated
from NF-B1, bcl-3, or GAPDH cDNAs, and blots were hybridized with
radiolabeled probes in Quickhyb (Stratagene). After a 2-h hybridiza-
tion, the blots were washed twice in 2 SSC, 0.1% SDS for 15 min at
room temperature and twice in 0.1 SSC, 0.1% SDS for 15 min at 60 °C.
Northern blots were analyzed by autoradiography.
Apoptosis Assay—LNCaP cells were plated at 5  105 cells per well
in a 6-well plate on day 0 and infected with adenovirus at 10 pfu/cell on
day 1. TNF was added to the media on day 2. After 24 h of incubation
with TNF, cells were harvested, and the extent of apoptosis was deter-
mined by quantitation of nucleosomes released into the cytoplasm using
the Cell Death Detection ELISA Plus kit (Roche Molecular Biochemi-
cals) according to the manufacturer’s directions.
RESULTS
The Transcriptional Activity of NF-B Is Inhibited by
PTEN—Our laboratory has demonstrated previously (15, 36)
that PI3K and Akt activate NF-B predominantly by targeting
the transactivation potential of the p65 subunit. Because
PTEN is the predominant negative regulator of Akt in vitro and
in vivo (1–6), we were interested in determining whether the
PTEN tumor suppressor gene product could inhibit NF-B
transcriptional activity. To address this question we used the
human prostate cell line LNCaP, in which endogenous Akt is
constitutively active due to inactivation of PTEN (40, 41).
LNCaP cells were transiently co-transfected with the NF-B-
responsive reporter 3-B-Luc and with wild-type PTEN or
various PTEN mutants. Functionally inactive mutants in-
cluded PTEN(C124S), which is defective in both protein and
lipid phosphatase activity, and PTEN(G129E), which is selec-
tively deficient in lipid phosphatase activity (7, 47). Following
transfection, LNCaP cells were subsequently treated with TNF
for 12 h, after which cell extracts were harvested and luciferase
activities were analyzed. Cells transfected with an expression
plasmid encoding wild-type PTEN displayed a reduction in
TNF-induced NF-B-dependent transcription, as compared
with cells transfected with the empty vector control (Fig. 1A).
The decrease in 3-B luciferase reporter activities observed
following the expression of PTEN was not due to cell death,
because an internal -galactosidase reporter displayed similar
levels of protein expression 12 h post-TNF addition (Fig. 1A).
Importantly, the ability of PTEN to suppress NF-B-dependent
transcriptional activity was associated with the lipid phospha-
tase activity of this tumor suppressor gene product, because
both PTEN(C124S) and PTEN(G129E) mutants were unable to
block effectively the TNF-induced NF-B transcriptional activ-
ity (Fig. 1A). In conclusion, re-introduction of PTEN into
LNCaP cells did not block basal NF-B activity but signifi-
cantly inhibited TNF-induced NF-B transcription (Fig. 1A).
These results indicate that constitutive Akt activity alone, due
to a loss of PTEN expression, was not enough to stimulate
NF-B activity and indicate that cellular stimulation is re-
quired for full NF-B activation, which can be blocked by PTEN
expression.
To determine whether the inhibition of NF-B-dependent
transcription by PTEN was specific to the ability of PTEN to
block PI3K-dependent stimulation of Akt, additional transient
reporter gene assays were performed. LNCaP cells were tran-
siently co-transfected with activated forms of Ha-Ras or cal-
modulin-dependent kinase kinase (CaMKK) in the presence of
either PTEN or vector control plasmid. Expression of activated
Ha-Ras(V12) in LNCaP cells effectively up-regulated the NF-
B-responsive reporter, which was blocked by co-expression of
PTEN protein (Fig. 1B). The expression of CaMKK, which is
known to directly activate Akt in a PIP3-independent manner
(48), induced the transcriptional activity of NF-B. NF-B ac-
tivation by CaMKK was not significantly blocked by PTEN
(Fig. 1B). These results indicate that PTEN is capable of inhib-
iting both TNF- and Ras(V12)-induced transcriptional activa-
tion of NF-B, presumably through its ability to down-regulate
PI3K-induced PIP3 levels.
To address further whether the ability of PTEN to block
TNF-induced NF-B transcription was associated with a down-
regulation of Akt activity, LNCaP cells were transfected with a
plasmid encoding a constitutively active Akt protein (M-Akt).
Due to a myristoylation motif, the M-Akt protein constitutively
inserts into the cytoplasmic membrane and no longer requires
PIP3 products generated by PI3K for kinase activity. Thus, we
would predict that M-Akt would bypass PTEN-mediated effects
and would allow TNF-dependent signals to activate NF-B
even in the presence of PTEN expression. As shown in Fig. 1C,
expression of M-Akt in LNCaP cells stimulated the transcrip-
tional activity of NF-B. These results suggest that the over-
expression of M-Akt acts to stimulate NF-B through mecha-
nisms different from endogenous Akt activity normally
displayed in LNCaP cells. Regardless, NF-B activity was in-
creased further in M-Akt-transfected cells following stimula-
tion with TNF (Fig. 1C). Consistent with the data presented in
Fig. 1A, PTEN blocked TNF-induced activation of NF-B. How-
ever, expression of M-Akt rescued PTEN-mediated suppression
of NF-B following TNF addition (Fig. 1C). The ability of M-Akt
to overcome PTEN-mediated effects on TNF-dependent activa-
tion of NF-B was not due to disproportionate transgene
expression, because Western blot analysis demonstrated ap-
propriate protein expression of PTEN, Akt, and the -galacto-
sidase control in co-transfection experiments (Fig. 1C). There-
fore, expression of a constitutively active Akt mutant
overcomes the ability of PTEN to block TNF-induced activation
of NF-B.
PTEN Inhibits NFB through Mechanisms Independent of
IB Degradation, p105 Processing, and p65 Nuclear Translo-
cation—To elucidate the molecular mechanisms by which
PTEN suppresses NF-B-dependent transcription, LNCaP
cells were infected with adenovirus directing the expression of
either PTEN (Ad-PTEN) or green fluorescent protein (Ad-
HA-tagged Ha-Ras(V12), and FLAG-tagged CaMKK proteins. C, constitutively active Akt rescues TNF-induced activation of NF-B following the
expression of PTEN. LNCaP cells were co-transfected with 3-B-Luc (0.5 g) and with empty vector control plasmid or expression constructs
encoding constitutively active Akt (M-Akt), wild-type PTEN, or M-Akt and PTEN (1 g each). Eighteen hours following transfections, cells were
stimulated with TNF (10 ng/ml). Cells were harvested 12 h following the addition of TNF, and luciferase activities were analyzed. Results represent
the mean  S.D. of three independent experiments performed in triplicate. Bottom panel, Western blot analysis demonstrating expression of
HA-tagged M-Akt, PTEN, and His-tagged -galactosidase.
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GFP). Adenoviral-mediated gene transfer is extremely efficient
in these cells where, at 10 plaque-forming units (pfu) of virus
per cell, 100% of cells display transgene expression (data not
shown). Nuclear and cytoplasmic extracts were isolated from
adenoviral infected cells following the addition of TNF over the
time course indicated. As shown in Fig. 2A, cytoplasmic pro-
teins isolated from LNCaP cells infected with Ad-PTEN dem-
onstrated PTEN protein expression, as compared with Ad-
GFP-infected control cells. Importantly, ectopic expression of
the PTEN protein was functional in LNCaP cells, because lipid
phosphatase activity of this tumor suppressor protein signifi-
cantly down-regulated the level of activated phospho-specific
Akt protein (Fig. 2A). The inability to detect phosphorylated
Akt in Ad-PTEN-infected cells was not due to differences in
protein loading, because similar levels of total Akt protein were
detected when blots were re-analyzed using a pan-Akt antibody
(Fig. 2A).
To elucidate whether PTEN expression blocks TNF-induced
phosphorylation and proteasome-dependent degradation of
IB, cytoplasmic extracts were analyzed for the presence of
IB protein. As shown in Fig. 2B, TNF-stimulated extracts
displayed a loss of IB protein with similar kinetics in both
Ad-GFP- and Ad-PTEN-infected LNCaP cells. Moreover, anal-
ysis of the p65 subunit of NF-B confirmed that the addition of
TNF led to an increase in nuclear accumulation regardless of
whether the cells overexpressed the PTEN tumor suppressor
gene product (Fig. 2E). Collectively, these results indicate that
PTEN did not inhibit the transcriptional activity of NF-B
through a mechanism that blocked IB degradation and nu-
clear translocation of p65 in LNCaP cells.
Because Akt has been reported to be required for TNF-
induced IKK activity (31, 39), LNCaP cells expressing PTEN
were analyzed for IKK activity following TNF stimulation. As
shown in Fig. 2C, LNCaP cells expressing PTEN displayed
similar TNF-induced IKK activity, as compared with control
cells. These results indicate that PTEN expression did not
block TNF-induced IKK activity in these cells. Moreover, al-
though LNCaP cells express constitutively active Akt, these
cells fail to display constitutive IKK activity.
PTEN has also been reported to negatively regulate NF-B
through mechanisms affecting p50 activity (38). Because p50
activity is regulated predominantly through IKK-dependent
phosphorylation and proteolysis of the p105 precursor protein
(49–51), we analyzed whether PTEN blocked p50 activity by
FIG. 2. TNF stimulates IKK-dependent IB degradation, p65
nuclear translocation, p105 processing, and NF-B DNA binding
activity in LNCaP cells despite PTEN expression. A, ectopic ex-
pression of PTEN efficiently down-regulates constitutively active Akt in
LNCaP cells. LNCaP cells were infected with adenovirus encoding
either green fluorescent protein (Ad-GFP) or PTEN (Ad-PTEN) at 10
pfu/cell. Twenty four hours following infection, cells were stimulated
with TNF (10 ng/ml) over the time course indicated, and nuclear and
cytoplasmic proteins were harvested from cells. Western blot analysis
was performed using cytoplasmic extracts, and ectopic expression of
PTEN was detected. Endogenous Akt activity was assessed using the
phosphospecific antibody that detects phospho-Ser-473 on Akt. Total
Akt protein levels were detected using a pan-specific antibody. B–E,
PTEN expression in LNCaP cells fails to inhibit IKK activity, TNF-
induced degradation of IB, p105 processing, and nuclear transloca-
tion of the p65 protein. B, cytoplasmic extracts (25 g/lane) from Ad-
GFP- and Ad-PTEN-infected LNCaP cells were analyzed for IB
protein levels following TNF stimulation. Total IB and -tubulin
protein levels were detected. C, TNF-stimulated LNCaP cells express-
ing either GFP or PTEN were analyzed for IKK activity. Whole cell
lysates (100 g) were immunoprecipitated with anti-IKK and incu-
bated with GST-IB-(1–54) in the presence of [-32P]ATP. Immuno-
precipitates and whole cell extracts were analyzed for IKK and PTEN
expression, respectively, by Western blot analysis. D, p50 activity was
measured as a function of p105 processing in TNF-stimulated LNCaP
cells expressing either GFP or PTEN. LNCaP cells were infected with
adenovirus, as described above, or treated with the proteasome inhib-
itor MG132 (20 M) 1 h prior to the addition of TNF for 30 min. Total
proteins (50 g/lane) were subjected to SDS-PAGE, and Western blots
were analyzed for protein expression. E, cytoplasmic (C) and nuclear
(N) extracts were analyzed for TNF-induced nuclear translocation of
the p65 subunit of NF-B. F, PTEN fails to block TNF-induced DNA
binding of NF-B. Nuclear proteins (8 g/reaction) were incubated with
a 32P-labeled double-stranded oligonucleotide corresponding to the
NF-B consensus site located in the MHC class I promoter. DNA-
protein complexes were resolved on a non-denaturing polyacrylamide
gel. The NF-B-specific complex (composed of p65 and p50) is indicated
by an arrow, as is a nonspecific (NS) band, which indicates relatively
equal amounts of nuclear extract in each reaction. An asterisk indicates
the p50 homodimer. Nuclear extracts isolated from LNCaP cells in-
fected with the Ad-SRIB and then treated with TNF served as a
positive control.
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inhibiting p105 processing in LNCaP cells following TNF stim-
ulation. LNCaP cells did not display significant increases in
p105 processing following the addition of TNF (Fig. 2D). More-
over, p50 levels did not change following the expression of
PTEN or following the addition of the proteasome inhibitor
MG132 (Fig. 2D). Consistent with Fig. 2B, PTEN also did not
block TNF-induced degradation of IB, but degradation was
blocked by pretreatment with MG132 (Fig. 2D). Therefore, in
contrast to previous reports (38), PTEN failed to block TNF-
induced NF-B activity through mechanisms involving p50
activation. Collectively, these results are consistent with our
findings that PTEN expression in LNCaP cells does not block
IKK-dependent IB degradation or p105 processing nor does
it affect p65 nuclear translocation following TNF stimulation
(Fig. 2, B, D, and E).
To elucidate whether PTEN expression affected TNF-in-
duced activation of NF-B through mechanisms involving DNA
binding, nuclear extracts were analyzed in EMSAs. As shown
in Fig. 2F, adenoviral infected LNCaP cells expressing PTEN
displayed similar NF-B DNA binding profiles following the
addition of TNF, as compared with cells receiving the Ad-GFP
control virus. Interestingly, nuclear extracts from LNCaP cells
infected with Ad-PTEN displayed slightly elevated DNA bind-
ing activity of NF-B at 1 h post-TNF addition, as compared
with Ad-GFP-infected cells (Fig. 2F). As a control, nuclear
extracts isolated from LNCaP cells infected with Ad-SRIB,
encoding a mutated form of IB that cannot be degraded
following TNF stimulation, failed to display TNF-induced
NF-B activity (Fig. 2F). Similar amounts of nuclear extracts
were analyzed in EMSAs, because the detection of a nonspecific
band displayed comparable levels of intensity in all lanes.
Moreover, re-analysis of nuclear extracts by EMSA displayed
equal levels of Oct-1-DNA binding complexes that served as a
loading control (data not shown).
To determine whether the PTEN effects were specific only to
LNCaP cells, we analyzed two other human prostate cell lines,
PC-3 and DU-145. PC-3 cells contain not only constitutive Akt
activity due to the loss of PTEN function (40, 41) but also
display constitutive IKK activation, DNA binding, and NF-B-
dependent transcription (52). On the other hand, DU-145 cells
express a functional PTEN protein (41) and consequently do
not display constitutive Akt activity. In this way, we could
determine whether PTEN expression blocked either basal or
TNF-induced nuclear translocation in either PC-3 or DU-145
cells. PC-3 and DU-145 were infected with Ad-GFP, Ad-PTEN,
or Ad-SRIB, and nuclear extracts were harvested following
TNF stimulation. Interestingly, expression of PTEN did not
block the high basal NF-B DNA binding activity normally
observed in PC-3 cells nor did it inhibit TNF-induced increases
in NF-B binding, as compared with Ad-GFP-infected control
cells (Fig. 3, left panel). Ectopic expression of PTEN also did not
inhibit TNF-induced NF-B nuclear DNA binding activity in
DU-145 cells (Fig. 3, right panel). However, expression of the
SR-IB protein blocked basal NF-B DNA binding activity in
PC-3 cells and also inhibited TNF-induced NF-B activity in
both PC-3 and DU-145 cells (Fig. 3). The inability of PTEN to
block TNF-induced nuclear translocation signals was not due
to differences in adenoviral mediated expression of PTEN, be-
cause PTEN was effectively expressed in both PC-3 and DU-
145 cells, and constitutively active phospho-Akt was down-
regulated in PC-3 cells (data not shown). We found that TNF
weakly stimulated Akt activity in DU-145 cells, and the expres-
sion of PTEN or exposure to the PI3K inhibitor, LY294002,
blocked TNF-induced NF-B transcriptional activity in tran-
sient reporter assays. However, consistent with the data here,
LY294002 failed to block TNF-induced nuclear translocation of
NF-B in DU-145 cells, as measured by EMSA (data not
shown). PTEN did not affect TNF-induced nuclear transloca-
tion and DNA binding of NF-B (composed of p65 and p50
heterodimer) in LNCaP, PC-3, or DU-145 cells. Therefore, de-
spite PC-3 cells displaying a loss of p50 homodimer binding
(compare Fig. 2F with Fig. 3), we predict that this effect could
not account for the ability of PTEN to inhibit NF-B-dependent
transcriptional activity. Collectively, these results indicate
that the expression of PTEN in LNCaP, PC-3, or DU-145 cells
failed to block NF-B DNA binding, suggesting that PTEN
functions to block NF-B-dependent gene expression through
an alternative mechanism.
PTEN Regulates NFB by Repressing the Transactivation
Domain of the p65 Subunit—To determine whether PTEN
could modulate NF-B by blocking the transactivation function
of p65, we utilized a plasmid encoding a Gal4-p65 fusion pro-
tein. In this fusion protein, sequences encoding the DNA bind-
ing domain of the yeast Gal4 transcription factor have been
joined with sequences encoding the transactivation domain I of
p65 (43). Experiments were performed by co-transfecting cells
with an expression plasmid encoding Gal4-p65 and with a
Gal4-responsive luciferase reporter (Gal4-Luc). In addition to
analyzing p65, we also evaluated whether PTEN could modu-
late the transactivation domain of CREB, a transcription factor
known to be directly phosphorylated by Akt (53), and c-Jun. As
shown in Fig. 4A, the transactivation potential of p65, CREB,
and c-Jun was increased in LNCaP cells following the addition
of TNF. The expression of PTEN blocked the ability of TNF to
stimulate the transactivation domain of p65 and CREB (Fig.
4A). Interestingly, PTEN expression did not inhibit the ability
of TNF to stimulate the transactivation domain of c-Jun (Fig.
4A). These results suggest that PTEN inhibits TNF-induced
NF-B activation by blocking the transactivation potential of
FIG. 3. Expression of PTEN fails to block TNF-induced nuclear
translocation and DNA binding activity of NF-B in PC-3 and
DU-145 prostate cells. PC-3 and DU-145 cells were infected with
Ad-GFP, Ad-PTEN, or Ad-SRIB virus (50 pfu/cell). Twenty four hours
following infection, cells were either left untreated or stimulated for 30
min with TNF (10 ng/ml), and nuclear extracts were isolated and
analyzed by EMSA. Arrows identify the NF-B-DNA binding complex
(composed of p65 and p50), the p50 homodimer (indicted by an asterisk),
and a nonspecific (NS) band that demonstrates that equal amounts of
total extract were analyzed in each lane.
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p65 and that down-regulation of PIP3 by PTEN expression also
modulates CREB transactivation function.
To understand better the signaling pathways by which
PTEN inhibits the transactivation potential of p65, we inves-
tigated whether active PI3K or Akt proteins could rescue PTEN-
dependent inhibition in response to TNF. As shown in Fig. 4B,
the expression of either PI3K or Akt proteins alone was capable
of up-regulating the transactivation potential of p65 above
vector control plasmid levels in unstimulated LNCaP cells.
This effect was further elevated following the addition of TNF
(Fig. 4B). PTEN expression failed to inhibit the ability of con-
stitutively active PI3K to target the transactivation domain of
p65 following TNF stimulation (Fig. 4B). Moreover, PTEN ex-
pression was unable to block the synergistic activation induced
by M-Akt following TNF stimulation (Fig. 4B). Therefore, these
results suggest that M-Akt can bypass the requirement for
PIP3 activity, although TNF still provides an inducible signal
(Fig. 4B).
Several reports including our own (15, 30, 36) have indicated
that IKK participates in targeting the p65 transactivation do-
main in response to activated Akt. Recently, we have shown
(36) that serine residues 529 and 536, located in the transac-
tivation domain of p65 and shown to be targeted by CK II and
IKK, respectively, are both required for Akt-induced activation
of NF-B. Therefore, although in Fig. 2D we demonstrate that
PTEN did not block the ability of IKK to phosphorylate IB
following TNF stimulation, additional transfection experi-
ments were performed to determine whether IKK alone was
enough to target the transactivation domain of p65 following
TNF stimulation. As shown in Fig. 4B, the expression of IKK
activated the transactivation domain of p65 in unstimulated
LNCaP cells, which was further enhanced following TNF stim-
ulation. PTEN was capable of inhibiting TNF-stimulated
LNCaP cells expressing wild-type IKK (Fig. 4B). These re-
sults suggest that in order for TNF to up-regulate the transac-
tivation domain of p65 in LNCaP cells, both Akt and IKK are
required. This hypothesis is supported by the observation that
co-expression of both M-Akt and IKK strongly activates the
p65 transactivation domain, without the need for TNF stimu-
lation (Fig. 4B). Moreover, this activation could not be inhibited
by the expression of PTEN (Fig. 4B).
To determine whether Akt and IKK are required for TNF-
dependent signals to target the transactivation potential of the
p65 subunit of NF-B, LNCaP cells were co-transfected with
Gal4-p65, the Gal4 reporter, and plasmids encoding for various
dominant negative proteins. As shown in Fig. 4C, cells express-
FIG. 4. PTEN blocks TNF-induced activation of NF-B by mod-
ulating the transactivation domain of p65. A, PTEN inhibits the
ability of TNF to stimulate the transactivation domain of the p65
subunit of NF-B. LNCaP cells were co-transfected with plasmids en-
coding the Gal4-p65, Gal4-CREB, or Gal4-cJun fusion proteins and
with the 4Gal4-Luc reporter. In addition, cells were transfected with
either the empty vector control or with an expression vector encoding
wild-type PTEN. Eighteen hours following transfection, cells were ei-
ther left untreated or were stimulated with TNF (10 ng/ml). Eighteen
hours following stimulation, cells were harvested, and luciferase activ-
ities were analyzed. Data presented represent the mean  S.D. of three
independent experiments. Bottom panel, Western blot analysis of cell
extracts demonstrate PTEN and Gal-4 protein expression. B, activated
forms of PI3K and Akt proteins overcome the ability of PTEN to block
TNF-induced stimulation of the p65 transactivation domain. LNCaP
cells were co-transfected with Gal4-p65, Gal4-Luc reporter, and with
plasmids encoding activated PI3K, Akt, IKK, Akt, and IKK or empty
vector control. Additionally, cells were co-transfected with plasmid
encoding PTEN or empty vector control. Eighteen hours following
transfection cells were either left untreated or were stimulated with
TNF (10 ng/ml). Cell extracts were harvested 18 h following the addi-
tion of TNF, and equal amounts of protein lysates were assayed for
luciferase activity. Data represent the mean  S.D. of two individual
experiments performed in triplicate. C, the ability of TNF to stimulate
the p65 transactivation domain is blocked by PTEN and dominant
negative forms of PI3K, Akt, and IKK. LNCaP cells were co-transfected
with Gal4-p65, Gal4-Luc reporter, and with expression plasmids en-
coding PTEN, dominant negative (DN) PI3K (p85), Akt(Lys 3 Met),
IKK (SS  AA). Eighteen hours following transfection cells were
stimulated with TNF, and 18 h following the addition of TNF, cells were
harvested, and luciferase activities were determined. Results represent
three separate experiments performed in triplicate, and the mean 
S.D. are shown.
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ing plasmids encoding PTEN or dominant negative PI3K, Akt,
or IKK all blocked the ability of TNF to stimulate the trans-
activation domain of p65 in LNCaP cells. Similar results were
observed in PC-3 cells, where expression of PTEN or dominant
negative constructs encoding PI3K, Akt, or IKK inhibited the
basal transactivation potential of the p65 subunit. The ability
of PTEN to inhibit the p65 transactivation domain was not
specific only to TNF, as this effect was also observed for inter-
leukin-1 (data not shown). These results indicate that PTEN
modulates NF-B transcriptional activity through a mecha-
nism that controls the transactivation function of the p65 sub-
unit and not by inhibiting signals that control nuclear translo-
cation or DNA binding of NF-B.
The Ability of PTEN to Block the Transactivation Potential of
the p65 Subunit of NFB Is Associated with a Loss of NF-B-
dependent Gene Expression—Our results suggest that the abil-
ity of PTEN to inhibit PIP3 and down-regulate Akt activity
alone is enough to inhibit the transactivation potential of the
p65 subunit, which would be predicted to block endogenous
NF-B-dependent gene expression (Fig. 4). To determine
whether the expression of PTEN blocked NF-B-dependent
gene expression following TNF stimulation, we analyzed the
expression of two NF-B regulated genes, NF-B1 and bcl-3
(54, 55). LNCaP cells were infected with either Ad-PTEN or
Ad-GFP control virus, RNAs were isolated, and Northern blot
analysis was performed. As shown in Fig. 5, LNCaP cells in-
fected with control virus displayed an increase in both NF-B1
and bcl-3 transcripts by 2 h, which persisted for 4 h following
TNF stimulation. Consistent with the ability of PTEN to block
NF-B transcriptional activity in transient reporter assays,
LNCaP cells expressing PTEN displayed a significant decrease
in both NF-B1 and bcl-3 transcripts (Fig. 5). The differences in
gene expression were not due to uneven loading of RNAs,
because re-analysis of blots for GAPDH displayed equal levels
of transcripts (Fig. 5). These results are consistent with our
finding that the ability of PTEN to down-regulate the transac-
tivation domain of p65 following TNF stimulation is associated
with a loss of NF-B-dependent gene expression.
PTEN Potentiates TNF-induced Apoptosis—Thus far, we
have established that the re-introduction of the PTEN tumor
suppressor protein into LNCaP cells affects the ability of these
cells to respond to TNF-induced NF-B transcriptional activa-
tion. Since it has been well established that TNF-induced ac-
tivation of NF-B is required to overcome the ability of this
cytokine to induce apoptosis (56–61), we next investigated the
effect of PTEN on cellular sensitivity to TNF-induced apo-
ptosis. As shown in Fig. 6, LNCaP cells became markedly
sensitized to TNF-induced apoptosis following Ad-PTEN infec-
tion at a dose as low as 10 ng/ml TNF for 24 h, as compared
with LNCaP cells infected with the Ad-GFP control. The his-
tone-associated DNA fragments detected using the Cell Death
Detection ELISA (Fig. 6), were also confirmed using standard
agarose gel electrophoresis analysis (data not shown). Collec-
tively, these results indicate that ectopic expression of PTEN in
LNCaP cells sensitized these cells to TNF-induced apoptosis.
This work is consistent with the idea that modulation of NF-B
transcriptional activity by the ability of PTEN to down-regu-
late Akt activity sensitizes the LNCaP cell line to TNF-induced
apoptosis.
DISCUSSION
In this report, we demonstrate that the down-regulation of
Akt activity by the re-introduction of the PTEN tumor suppres-
sor protein in prostate epithelial cells inhibits the ability of
TNF to stimulate NF-B-dependent transcription. The ability
of PTEN to block TNF-induced activation of NF-B is depend-
ent on the lipid phosphatase activity of PTEN and on the
concomitant down-regulation of Akt activity. In support of this,
we found that constitutively active Akt overcame the ability of
PTEN to suppress NF-B activation following TNF stimula-
tion. CaMKK, which has been shown to activate Akt through
PI3K-independent pathways (48), was capable of activating
NF-B even in the presence of PTEN. In our model system, the
inhibition of Akt activity by the expression of PTEN did not
block TNF-induced IKK activation, IB degradation, p105
processing, p65 nuclear translocation, or DNA binding of NF-
B. Rather, cells expressing PTEN displayed equal or even
better NF-B DNA binding activities following TNF stimula-
tion, as compared with cells expressing GFP control protein. To
determine mechanistically how PTEN-dependent inhibition of
Akt blocked the ability of TNF to stimulate NF-B, we evalu-
ated whether PTEN down-regulated the transactivation poten-
tial of the p65 subunit of NF-B. We found that PTEN inhibited
the ability of TNF to stimulate the transactivation potential of
p65, as well as CREB, but not c-Jun. The transactivation po-
tential of p65 following TNF stimulation could be rescued from
FIG. 5. Reintroduction of PTEN into LNCaP cells blocks TNF-
induced NF-B-dependent gene expression. LNCaP cells were in-
fected with either Ad-GFP or Ad-PTEN. Twenty four hours following
infection cells were either left untreated or were stimulated with TNF.
Total RNAs were isolated, resolved on a formaldehyde gel, and blotted
onto nitrocellulose. Gene expression for NF-B1, bcl-3, and GAPDH
were determined by analyzing Northern blots with radiolabeled cDNAs
corresponding to these genes. Equal amounts of RNA were loaded in
each lane because no differences were observed for GAPDH expression.
FIG. 6. Ectopic expression of PTEN sensitizes LNCaP cells to
TNF-induced apoptosis. Subconfluent LNCaP cells were infected
with either Ad-GFP or Ad-PTEN (10 pfu/cell) 24 h prior to the addition
of varying concentrations of TNF (0, 10, 20, and 40 ng/ml). Twenty four
hours following the addition of TNF, adherent and non-adherent cells
were harvested and assayed for the presence of histone-associated DNA
fragments using the Cell Death Detection ELISA kit (Roche Molecular
Biochemicals). Relative apoptosis was plotted, where Ad-GFP-infected
LNCaP cells grown in the absence of TNF was normalized to one. Data
presented were performed in duplicate, and similar results were ob-
tained in three independent experiments. Western blot analysis for
PTEN expression demonstrated transgene expression over the 48-h
time course of the experiment.
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PTEN-dependent repression by re-introducing activated forms
of PI3K and Akt or Akt and IKK. The ability of TNF to stim-
ulate the transactivation domain of p65 was not only blocked by
PTEN but also by the expression of dominant negative forms of
PI3K, Akt, or IKK proteins. These results suggest that all of
these signaling molecules are important for full NF-B-depend-
ent transcriptional activity. Modulation of the transactivation
function of p65 by PTEN is important for NF-B-dependent
transcription, because PTEN blocked TNF-induced up-regula-
tion of NF-B1 and bcl-3 transcripts. Consistent with a previ-
ous report (16) that used a PI3K inhibitor, we find that expres-
sion of PTEN results in a loss of Akt and NF-B activities and
sensitizes LNCaP cells to TNF-induced apoptosis.
During the preparation of this manuscript, two other inde-
pendent reports were published that address the effect of the
PTEN tumor suppressor gene expression on NF-B activation
following stimulation by proinflammatory cytokines (38, 39).
The basic conclusion in both of these studies was that PTEN
was capable of inhibiting NF-B-dependent gene expression in
transient reporter gene assays. However, some major discrep-
ancies exist between our results and the other reported molec-
ular mechanisms by which PTEN inhibited NF-B (38, 39). In
the other studies, it was argued that expression of PTEN,
either transiently or stably, results in a loss of NF-B DNA
binding potential. Under no circumstances did we observe this
effect in any of the cell lines we tested. Rather, as shown in
Figs. 2E and 3, expression of PTEN results in a slight increase
in NF-B DNA binding following TNF stimulation. This effect
was not specific to TNF, because PTEN also failed to block
NF-B-DNA binding activity in LNCaP cells following IL-1
stimulation.2 Koul et al. (38) also indicated that PTEN expres-
sion down-regulated the p50:p50 homodimer DNA-binding
complex of NF-B. Although we did observe this effect in PC-3
cells, this mechanism did not account for PTEN-dependent
inhibition of NF-B activity and was not observed in either
LNCaP or DU-145 cells (Fig. 2E and 3). In contrast, in our
model system PTEN did not block TNF-induced DNA binding
of the transcriptionally active p65:p50 heterodimer of classical
NF-B. Gustin et al. (39) indicated that PTEN expression
blocks the ability of the IKK complex to stimulate IB phos-
phorylation. Our data strongly indicate that this is not the case
in LNCaP, PC-3, or DU-145 cells. On the contrary, we observed
instead a normal increase in IB phosphorylation and degra-
dation and nuclear translocation of p65 (Fig. 2, B, D, and E and
data not shown). Moreover, LNCaP cells expressing PTEN
display normal TNF-induced IKK activity, indicating that
PTEN does not block the ability of IKK to phosphorylate IB
(Fig. 2C). If PTEN was functioning to inhibit the ability of the
IKK complex to phosphorylate IB, then one would predict that
PTEN-deficient cells would maintain constitutive Akt phospho-
rylation and IKK activity and display constitutive NF-B DNA
binding. However, these results are not what was observed in
LNCaP cells nor what was reported for PTEN null MEF cells
(6). In contrast, cells constitutively expressing active Akt still
require a stimulus to induce IB degradation, DNA binding,
and NF-B-dependent gene expression. This is supported not
only in our study, but also in other recent reports (38, 39). Our
results and the results of others (38) indicate that constitu-
tively active endogenous Akt alone is not enough to activate
effectively the IKK-dependent pathways. Conversely, the inhi-
bition of Akt via PTEN is incapable of fully inhibiting IKK
activity and IB phosphorylation and degradation (Fig. 2,
B and C) (38).
The ability of PTEN to block NF-B-dependent gene expres-
sion and sensitize cells to TNF-induced apoptosis may allow
insight into the use of pharmacological inhibitors of the PI3K
pathway to therapeutically treat human tumors that have lost
functional PTEN expression. NF-B is known to protect cells
from apoptosis by up-regulating target genes that restrict cy-
tochrome c release from the mitochondria and inhibit caspase
activation. To date, these NF-B-regulated genes include
cIAP-1, cIAP-2, XIAP, Bcl-XL, Al/Bfl-1, Nrl3, IEX-1L, and the
recently discovered NDED (61, 62). Although the down-regula-
tion of PI3K activity has been shown to induce apoptosis that
can be rescued by the overexpression of the p65 subunit of
NF-B (16), we cannot exclude the possibility that PTEN in-
duces cell death through other mechanisms as well. For exam-
ple, as we have described here, another pro-survival transcrip-
tion factor, CREB, is also negatively regulated by PTEN
activity. Huang et al. (63) recently reported similar results
indicating that PTEN-mediated repression of phosphorylation
of CREB at serine 133 was associated with the transcriptional
down-regulation of the bcl-2 protooncogene in human prostate
cells. Because Akt has been shown recently (64) to provide
protection from the TRAIL/Apo-2L pathway by inhibiting BID
cleavage, it is possible that the inhibition of Akt via PTEN
expression would sensitize prostate cells to similar death path-
ways initiated by TNF. Moreover, because Bcl-2 and Bcl-XL
block TRAIL-induced apoptosis, it could be that a combination
of these different signaling events is required to allow PTEN to
sensitize prostate cells to apoptotic stimuli.
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